Abstract
Intramuscular (IM) injection of epinephrine as first-line treatment for acute allergic reactions and anaphylaxis presents some challenges that can lead to incorrect administration or delays in use. AQST-109 is the first and only sublingual film using a novel prodrug of epinephrine (DESF) being developed for the same target indication as epinephrine injection in the emergency treatment of Type 1 allergic reactions. This study was conducted to compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of epinephrine following administration of sublingual DESF versus 0.3 mg IM injection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
